Global Malignant Mesothelioma Therapeutics Market 2019-2023 | Evolving Opportunities with Bristol-Myers Squibb Co. and Eli Lilly and Co. | Technavio

LONDON–(BUSINESS WIRE)–#Biotechnology–The global malignant mesothelioma therapeutics market is poised to grow by USD 133.81 million during 2019-2023, progressing at a CAGR of almost 7% during the forecast period. Request Free Sample Pages

Read the 125-page research report with TOC on “Malignant Mesothelioma Therapeutics Market Analysis Report by Product (Chemotherapy and Other therapeutics), by Geography (North America, Europe, Asia, and ROW), and Segment Forecasts, 2019 – 2023.”

https://www.technavio.com/report/global-malignant-mesothelioma-therapeutics-market-industry-analysis

The market is driven by the rising use of asbestos for commercial purposes. In addition, the increasing awareness of malignant mesothelioma is anticipated to further boost the growth of the malignant mesothelioma therapeutics market.

The rising use of asbestos for commercial purposes will be one of the major drivers in the global malignant mesothelioma therapeutics market. Over the years, the use of asbestos has increased significantly in various applications such as machines, building materials, and transport vehicles. People working in industries that have extensive asbestos applications are regularly exposed to the material and have higher chances of being predisposed to asbestos-related diseases. Thus, the extensive use of asbestos for commercial purposes will drive the global malignant mesothelioma therapeutics market during the forecast period.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Major Five Malignant Mesothelioma Therapeutics Market Companies:

Bristol-Myers Squibb Co.

Bristol-Myers Squibb Co. operates the business under the biopharmaceuticals segment. This segment is involved in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of innovative medicines. The company offers a wide range of malignant mesothelioma therapeutics. Some of the products offered by the company are PLATINOL, OPDIVO, YERVOY, and PARAPLATIN.

Eli Lilly and Co.

Eli Lilly and Co. operates the business under the following two segments, which include human pharmaceutical products and animal health products. The company’s key offerings include ALIMTA and GEMZAR.

F. Hoffmann-La Roche Ltd.

F. Hoffmann-La Roche Ltd. has business operations under the pharmaceuticals and diagnostics segments. The product offered by the company is AVASTIN which is a vascular endothelial growth factor-specific angiogenesis inhibitor used for the treatment of various cancers such as colorectal cancer, NSCLC, and breast cancer.

Merck & Co. Inc.

Merck & Co. Inc. operates the business under the following three segments, which include pharmaceuticals, animal health, and others. The company’s key offering include KEYTRUDA which is a programmed death receptor-1 (PD-1)-blocking antibody used for the treatment of various cancers such as NSCLC, head and neck squamous cell cancer, urothelial carcinoma, gastric cancer, and cervical cancer.

Pfizer Inc.

Pfizer Inc. operates the business under the following segments: innovative health and essential health. The company’s key offering in the malignant mesothelioma therapeutics market include TOMUDEX which is an intravenous powder solution for injection or infusion. It is used for the treatment of mesothelioma of the pleura.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio’s SUBSCRIPTION platform

Malignant Mesothelioma Therapeutics Product Outlook (Revenue, USD Million, 2019 – 2023)

• Chemotherapy
• Other therapeutics

Malignant Mesothelioma Therapeutics Regional Outlook (Revenue, USD Million, 2019 – 2023)

• Asia
• Europe
• ROW
• North America

Technavio’s sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at [email protected].

Contacts

Technavio Research

Jesse Maida

Media & Marketing Executive

US: +1 844 364 1100

UK: +44 203 893 3200

www.technavio.com
[email protected]